TYK Medicines Inc

TYK Medicines, Inc. is a clinical-stage biopharmaceutical company engaged in the research, development, and commercialization of pharmaceutical products. Its lead candidate, TY-9591, is a third-generation EGFR tyrosine kinase inhibitor for EGFR-mutated non-small cell lung cancer (NSCLC) with brain metastases and for locally advanced or metastatic NSCLC with the EGFR L858R mutation. The company also develops TY-302 (oral CDK4/6 inhibitor), TY-2136b (oral ROS1/NTRK inhibitor), TY-2699a (selective CDK7 inhibitor), TY-0540 (selective CDK2/4/6 inhibitor), TY-1054 (oral YAP-TEAD inhibitor), a preclinical oral CDK4 inhibitor, TY-3002 (oral small-molecule GLP-1 receptor agonist), and EGFR/FAK (PROTAC) and PI3Kα programs, as well as GLP-1 for type 2 diabetes and overweight or obesity. It has a collaboration agreement with Qilu for the development, manufacturing, and commercialization of TY-9591. Incorporated in 2017, the company is headquartered in Huzhou, China.